Mayinglong Pharmaceutical Group Co.Ltd(600993) recently announced that it plans to contribute 37.75 million yuan as a limited partner to subscribe for the share of the partnership, accounting for 37.51% of the total subscribed capital of the partnership.
Mayinglong Pharmaceutical Group Co.Ltd(600993) said that in order to expand investment channels, obtain investment income, expand industrial resources and promote the development of the company’s big health industry, the company signed the partnership agreement of Changzhou Fuquan Jianlong venture capital partnership (limited partnership) with China venture capital, Jiahua Huijin and other partners on December 16, 2021. If the scale of the follow-up fund reaches the target fund-raising scale of 250 million yuan, it is expected that the proportion of the company’s subscribed capital contribution to the fund will be reduced to 15.10%.
According to the announcement, the name of the proposed fund is Changzhou Fuquan Jianlong venture capital partnership (limited partnership) (tentative name, subject to industrial and commercial approval), the organizational form is limited partnership, the executive partner is Beijing Jiahua Huijin Investment Management Co., Ltd., and the fund management organization is Beijing Jiahua Huijin Investment Management Co., Ltd.
Mayinglong Pharmaceutical Group Co.Ltd(600993) said that on the premise of ensuring the funds required for daily operation and development, the company uses its own funds to subscribe for the target fund, which is conducive to timely grasp investment opportunities and improve the efficiency of fund use through a professional investment management team. At the same time, it helps to accumulate project resources, further expand potential cooperation opportunities in biomedicine and big health industries, and improve the industrial layout.
(China Securities Journal · China Securities Network)
